Communiqués Immutep Limited

Actions

IMM

AU000000IMM6

Marché Fermé - Australian S.E. Autres places de cotation 08:11:03 07/06/2024			Varia. 5j.	Varia. 1 janv.
0,43 ^AUD	+1,18 %		-4,44 %	+24,64 %

05/06	Immutep complète son offre d'actions	MT
03/06	Immutep Limited annonce une collaboration clinique avec Msd pour évaluer l'Efti en combinaison avec Keytruda® ? (Pembrolizumab) dans le cadre d'un essai clinique pivot de phase II	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Immutep : successfully completes institutional placement and institutional component of entitlement offer	05/06	PU
Immutep Announces Clinical Collaboration with MSD to Evaluate Efti in Combination with KEYTRUDA® (pembrolizumab) in Pivotal Phase III Trial	03/06	AQ
Immutep Presents Data from Safety Lead-in Phase of AIPAC-003 at ESMO Breast 2024	15/05	AQ
Immutep : ESMO Breast 2024 AIPAC 003 Poster (Metastatic Breast Cancer)	15/05	PU
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma	02/05	AQ
Immutep Quarterly Activities Report Q3 FY24	29/04	AQ
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761	18/04	AQ
Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	18/04	PU
Immutep : Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP76	18/04	PU
Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	17/04	AQ
Immutep : Corporate Presentation	26/03	PU
Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)	06/03	PU
Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)	05/03	PU
Immutep Announces First Clinical Data from 90mg Dosing of Efti	05/03	AQ
Immutep Quarterly Activities Report Q2 FY24	30/01	AQ
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer	04/01	AQ
Immutep : Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer	21/12	PU
Immutep Receives A$2.6 million R&D Tax Incentive from French Government	07/12	AQ
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial	22/11	AQ
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma	10/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Immutep Limited

Actions

IMM

AU000000IMM6

Communiqués

Filtres